AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00712062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2 given as an injection into a vein over 10 minutes once every 21 days until progression or unacceptable toxicity.
Study NCT02036554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.
Study NCT03684928 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comfilcon A (test)
Description: Daily wear contact lenses
Study NCT03684928 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Senofilcon C (control)
Description: Daily wear contact lenses
Study NCT02821676 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PECI/SPB Block with Active Anesthetic + Placebo Multilevel Intercostal Nerve Block followed by Latissimus Dorsi Flap Breast Reconstruction
Description: 30mL of 0.5% Ropivacaine with 1:200,000 epinephrine preoperatively via an ultrasound guided PECI/SPB regional block and 5mL of Normal Saline intraoperatively as an intercostal nerve block to each of the T2-T7 nerve segments
Study NCT01423864 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: conventional ECMO with intravenous steroid
Description: refractory acute respiratory distress syndrome and multi-organ dysfunction syndrome treated with intravenous steroid, Solu-Cortef 50mg q6h taper down when hemodynamic stable
Study NCT03180762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered.
Study NCT02948075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quisinostat
Study NCT02948075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT02948075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT02382263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel 150 mg/m2 + Gemcitabine 1000 weeks 1,3/4
Description: Nab-paclitaxel 150 mg/m2 + Gemcitabine 1000 days 1 \& 15 in a 28 days cycle
Study NCT02382263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel 100 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4
Description: Nab-paclitaxel 100 mg/m2 + Gemcitabine 1000 days 1,8 \& 15 in a 28 days cycle
Study NCT02036554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.
Study NCT02036554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.
Study NCT02382263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,3/4
Description: Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 days 1 \& 15 in a 28 days cycle
Study NCT02382263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4
Description: Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 days 1,8 \& 15 in a 28 days cycle
Study NCT03816826 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy
Description: both are physical therapy intervention technique used to treat the soft tissue acute injuries
Study NCT04674904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Dry needling on Upper trapezius, Levator Scapulae, Sternocledomastoid , Pectorals major and minor and rhomboids for 10 min
Study NCT04674904 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hot pack , TENS , Stretching
Description: Treatments are~1. Hot Pack for 15 minutes~2. TENS for 10 minutes~3. Stretching~The third treatment which is Stretching will be given one time on each muscle (tight upper trap, Levator Scapulae, Sternocledomastoid , Pectorals major and minor and rhomboids) of upper spine
Study NCT00553475 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Dosage: placebo, oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
Study NCT00553475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: Dosage: 300 mg/day (150 mg bid), oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
Study NCT00553475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: Dosage: 600 mg/day (300 mg bid), oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
Study NCT02916433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Study NCT02036554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolic acid
Description: Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.
Study NCT04059367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC9204-1177
Description: Increasing doses of NNC9204-1177 administered s.c. (subcutaneously, under the skin) in the stomach area once-weekly for 11 weeks
Study NCT04059367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocktail of 5 already approved drugs
Description: 5 medicines as tablets, capsules or syrup to be taken with water on Day 1 and Day 78 of the study
Study NCT01652300 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: two educational sessions
Description: The test group had two educational sessions lasting 1 hour, focused on oral and dental health and especially on oral and dental health during pregnancy
Study NCT01652300 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: no education
Description: women in the control group received no education
Study NCT03754231 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart rate monitoring
Description: The heart rate of recruited patients will be monitored for 15 minutes over 2 phases:~i) 10 minutes at rest ii) 5 minutes during physical activity in the form of walking or playing
Study NCT03754231 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory rate monitoring
Description: The heart rate of recruited patients will be monitored for 15 minutes over 2 phases:~i) 10 minutes at rest ii) 5 minutes during physical activity in the form of walking or playing
Study NCT00752596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azimilide 2HCl
Description: One tablet of 125 mg/day azimilide 2HCl, taken until the study is terminated
Study NCT02678598 — intervention group
Intervention type: DRUG
Intervention: Micafungin
Description: Intravenous
Study NCT01092065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFQ056 with L-dopa
Description: hard gelatin capsule to be taken bid for six weeks
Study NCT01092065 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: hard gelatin capsule to be taken bid for six weeks
Study NCT03410264 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CR-EXP
Description: See arm/group descriptions
Study NCT03410264 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EXP-CR
Description: See arm/group descriptions
Study NCT03410264 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management
Description: See arm/group descriptions
Study NCT00540371 — intervention group
Intervention type: OTHER
Intervention: Port wine stain Birthmark
Description: Port wine stain Birthmark
Study NCT03538574 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-I
Description: CBT-I is a behavioral treatment for insomnia
Study NCT03538574 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MAP-I
Description: MAP-I is a mindfulness meditation treatment for insomnia
Study NCT03383705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VBeam Prima
Description: Up to four treatments will be performed every 4-6 (±1) weeks.
Study NCT03761771 — intervention group
Intervention type: DEVICE
Intervention: colonoscopy withdrawal with the ADS monitoring
Description: During the testing of trained ADS, when the system doubts colonic lesions from the input data of the test images, a rectangular frame was displayed in the endoscopic image to surround the lesion. If the system confirmed it as the colonic lesions, a sound of reminder will be played and the types of lesions (non-adenomatous polyps, adenomatous polyps and colorectal cancers) will be classified by the system. We adopted several standards to define the identification and classification of colonic lesions: 1) when the system identified and confirmed any lesion in the images of no polyps or cancers, the results were judged to be false-positive. 2) when the system both confirmed and correctly localized the lesions in images (IoU > 0.3), the results were judged to be true-positive. 3) when the system did not confirm or correctly localize the lesions, the results were judged as false-negative. 4) when system confirmed no lesions in the normal images, the results were judged to be true-negative.
Study NCT00064298 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fruit and vegetable extracts
Description: Given orally
Study NCT00064298 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT04211233 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: invasive subdural grid electrode
Description: A subdural EEG-electrode (PLATIN 1x4 or 1x6; Ad-Tech Medical Instrument Corporation, Oak Creek, WI, USA, Figure 1) will be implanted in the subdural space frontotemporal intraoperatively and diverted separately from the wound area. Afterwards, invasive Monitoring will be performed for 7 days and the grid will be removed simply by pulling out.
Study NCT04211233 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control arm
Description: Standard Treatment based on Brain Trauma Foundation
Study NCT04144465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NORADRENALIN
Description: DRUG THAT IS IMPROVING TISSUE AND ORGAN PERFUSION
Study NCT04144465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PHENYLEPHRINE
Description: DRUG THAT IS IMPROVING TISSUE AND ORGAN PERFUSION
Study NCT04381338 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary and Motor Rehabilitation
Description: Pulmonary and Motor Rehabilitation in ICU
Study NCT01486810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine
Description: Patients will be titrated to the tolerated dose over a two week period, with a maximum of 140mg daily, and then maintained on the highest tolerated dose for four weeks
Study NCT01486810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: medication management
Description: All participants will receive medication management counseling and individual therapy using a structured compliance enhancement manual designed for pharmacotherapy trials in subjects with substance use disorders.
Study NCT00983697 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Study NCT00983697 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Study NCT04651101 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: coronary angiography
Description: extent of coronary artery disease in invasive coronary angiography
Study NCT04010539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gepotidacin
Description: Gepotidacin will be administered as 3000 milligram (mg) oral dose (4 X 750 mg tablets) at the study site followed by 3000 mg oral dose (4 X 750 mg tablets) as an outpatient. Each dose should be taken after food consumption and with water.
Study NCT04010539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone
Description: Ceftriaxone is available as sterile powder for reconstitution. It will be administered as one 500-mg IM dose at the study site.
Study NCT04010539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin will be administered as 1000 mg oral dose (2 X 500 mg tablets) at the study site. Dose should be taken after food consumption and with water.
Study NCT01951859 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropathy/Ulcer Homeopathic topical cream
Description: This is a GRAS topical agent containing homeopathic ingredients
Study NCT01216605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syntocinon 24 IU
Study NCT01216605 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01989260 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Anti-adhesive gel
Description: 4mls of anti-adhesive gel coated to the randomized ovary
Study NCT04268849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferumoxytol
Description: Ferumoxytol (30 mg/mL) intravenous injection in single use vials.
Study NCT04268849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Placebo for Ferumoxytol
Study NCT04268849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate tablets
Description: ferrous sulfate tablets containing 60 mg elemental iron
Study NCT04268849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: Placebo: Vitamin C, 250 mg, given in the same bottle as the oral iron
Study NCT02045303 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact Ultrasound Therapy
Description: Following our protocol, the ultrasound wound therapy will start with contact ultrasound until it meets criteria to switch to noncontact ultrasound therapy.
Study NCT02045303 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noncontact Ultrasound Therapy
Description: Transition from contact to noncontact ultrasound when criteria for transition is met per our protocol.
Study NCT00721903 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Scan
Description: 10 female volunteers with normal breast who will be studied to refine imaging techniques and for comparison with patients. To the degree possible, the volunteer group will be age-matched to patients with symptoms, initially 30 to 70 years of age.
Study NCT00721903 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mammography and Ultrasound
Description: To determine how well from ultrasound scans, changes in malignant masses can be measured, and to whether the use of a dye visible by ultrasound will be useful in evaluating different therapies for breast cancer.
Study NCT02264873 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Decitabine
Description: Dose escalation starting at 5 mg, and increasing by 2.5 mg to a Dose Level of 12.5 mg qd x 3 days.
Study NCT04612023 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acellular Amniotic Membrane Derived Allograft Injection (NuDYN)
Description: Injectable acellular amniotic membrane derived allograft tissue (NuDYN) through routine follow-up with physical examination, pain, function and quality of life measurements and compare dose effects (1 mL versus 2 mL of NuDYN injection) to a placebo (sterile saline) in the treatment of knee osteoarthritis. Injection is minimally invasive and is FDA regulated (HCT/P regulation).
Study NCT04612023 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Acellular Amniotic Membrane Derived Allograft Injection (NuDYN)
Description: Injectable acellular amniotic membrane derived allograft tissue (NuDYN) through routine follow-up with physical examination, pain, function and quality of life measurements and compare dose effects (1 mL versus 2 mL of NuDYN injection) to a placebo (sterile saline) in the treatment of knee osteoarthritis. Injection is minimally invasive and is FDA regulated (HCT/P regulation).
Study NCT01150474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belladonna and Opium Suppositories
Description: Belladonna (16.2 mg) and opium (60 mg) suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.
Study NCT01150474 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Suppositories
Description: Placebo suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.
Study NCT03533686 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adhear Bone Conduction System
Description: Non-invasive bone conduction hearing device using adhesive
Study NCT03533686 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone anchored hearing aid (BAHA)
Description: Non-invasive bone conduction hearing device using a headband
Study NCT01856023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Dose Interleukin-2
Study NCT01856023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Study NCT01585012 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical cap (Focus Touch™ Conception System)
Description: Cervical cap
Study NCT01797172 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Cervical Nucleoplasty
Description: Cervical nucleoplasty is a method of percutaneous disc decompression using a 19 Gauge Trocar 3 inch spine needle (ArthroCare Co., Sunnyvale, CA, USA) which is brought to the annulus fibrosis of the herniated disc. If in the correct position, the stylet is withdrawn and the Perc DC SpineWand (ArthroCare Co., Sunnyvale, CA, USA) is introduced. The procedure relies on so-called Coblation technology which involves removing a portion of the nucleus tissue by using radio frequency energy. More specific, it results in ablation of a portion of nucleus tissue, not with heat, but with a low-temperature (typically 40-70° C) plasma field of ionized particles.
Study NCT01797172 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed Radio Frequency
Description: Pulsed Radio Frequency involves placement of a needle close to the to-be-treated nerve or dorsal root ganglion (DRG). The position is checked radiographically and by motor and sensory nerve stimulation. When the needle has been placed correctly an electrode is introduced, which conducts short bursts of radio frequency energy to nervous tissue. It is known as a non- or minimally neurodestructive technique, alternative to radio frequency heat lesions using so-called thermocoagulation. No nerve damage takes places as the temperature of the tip of the needle does not exceed 42°C. This is achieved by relatively long pauses between pulses which allow generated heat to dissipate and prevent the development of any thermal lesion.
Study NCT02345746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: infusion over 12 hours via HAI
Study NCT02345746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: as a 2-hour infusion via HAI on day 2
Study NCT02345746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Following Folinic Acid as a continuous infusion over 48 hours on days 2, 3
Study NCT00384111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zevalin Therapeutic Regimen
Description: Day 1: 250 mg/m2 Rituxan followed by 5 mCi 111In Zevalin. Day 7: 250 mg/m2 Rituxan followed by 0.4 mCi/kg Zevalin
Study NCT00384111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CVP
Description: Standard R-CVP
Study NCT00384111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-CVP
Description: Standard R-CVP
Study NCT00245583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: minimum does of 50mg/day
Study NCT00245583 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching tablet
Study NCT00868179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pradax
Description: Pradax (dabigatran etexilate) is a prodrug that when converted to the active from in the liver and plasma it becomes a reversible, competitive direct thrombin inhibitor. Thrombin catalyses the conversion of soluble fibrinogen into soluble fibrin, the final step in the coagulation cascade. Pradax competitively blocks the active site of both free and clot-bound thrombin, preventing the development of a thrombus. they will take 110 mg 1-4 hours post op. and 220mg daily until 10 days post op.
Study NCT00829283 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Weight Loss
Description: weekly individual sessions for 6 months
Study NCT00829283 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss
Description: weekly individual sessions for 6 months
Study NCT00829283 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss + Guided self-help Cognitive-behavioral Therapy
Description: weekly BWL sessions for 4 weeks and 6-8 CBT sessions for 5 months
Study NCT01423864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solumedrol
Description: Initially, intrapleural steroid administration was performed using 40 mg solumedrol q6h (for both the pleural cavities). If chest radiography showed an improvement in consolidation, i.e., 0.8 > FiO2 ≥ 0.5 and 5 ≤ PEEP ≤ 10, the dosage of solumedrol was reduced to 40 mg q12h. When FiO2 was below 0.5 and the PEEP was below 10, the dosage of solumedrol was lowered to 40 mg qd for 3 days and then its administration was discontinued.
Study NCT01358448 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: growth monitoring
Description: Caretakers will be encouraged to monitor child growth monthly.